Drug-induced thrombotic microangiopathy: incidence, prevention and management

Area of Science:

• Nephrology
• Hematology
• Oncology

Background:

• Thrombotic microangiopathy (TMA) is a syndrome characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ damage due to microcirculation platelet thrombi.
• While infections are common causes in children, adults present with diverse etiologies including transplantation, pregnancy, immune disorders, and drug exposure.
• Drug-induced TMA, though rare, significantly contributes to morbidity and mortality.

Purpose of the Study:

• To highlight the critical importance of early diagnosis for drug-induced thrombotic microangiopathy (TMA).
• To emphasize the need for vigilant monitoring in patients receiving potentially toxic therapies.
• To discuss current management strategies and the need for further research.

Main Methods:

• Review of literature on drug-induced thrombotic microangiopathy (TMA).
• Analysis of reported cases associated with various medications, particularly antineoplastics.
• Discussion of diagnostic criteria and monitoring parameters.

Main Results:

• Antineoplastic agents, notably mitomycin, are frequently implicated in drug-induced TMA.
• Other implicated drugs include cyclosporine, tacrolimus, OKT3, interferon, anti-aggregating agents, and quinine.
• Early detection through strict monitoring of renal function, blood/urine parameters, and blood pressure is crucial.

Conclusions:

• Prompt discontinuation of the suspected causative agent is paramount in managing drug-induced TMA.
• Empirical treatments, including plasma exchange, have been used, but their efficacy requires validation through rigorous clinical trials.
• Further multicenter, randomized studies are necessary to establish definitive treatment protocols for TMA.